Madison Asset Management LLC Makes New Investment in Labcorp Holdings Inc. $LH
Madison Asset Management LLC has made a significant new investment in Labcorp Holdings Inc. (NYSE:LH), purchasing over 476,000 shares valued at approximately $133.46 million, making it their 13th largest holding. Other institutional investors have also adjusted their positions in Labcorp, and company insiders have recently sold shares. Labcorp reported strong quarterly earnings, beating analyst expectations, and several analysts have set new price targets for the stock, with a consensus "Moderate Buy" rating.
Tocqueville Asset Management L.P. Takes $22.67 Million Position in Quest Diagnostics Incorporated $DGX
Tocqueville Asset Management L.P. recently acquired a new stake of 106,964 shares, valued at $22.67 million, in Quest Diagnostics Incorporated (NYSE:DGX). This makes Tocqueville Asset Management L.P. one of several institutional investors to either boost or initiate positions in DGX. The article also details recent insider stock transactions, Quest Diagnostics' financial performance, dividend announcement, and updated analyst price targets.
20,883 Shares in Labcorp Holdings Inc. $LH Purchased by Great Lakes Advisors LLC
Great Lakes Advisors LLC has acquired 20,883 shares of Labcorp Holdings Inc. (NYSE:LH) in the second quarter, valuing their new stake at approximately $5.85 million. Institutional investors collectively hold 95.94% of the company's stock, and analysts maintain a "Moderate Buy" rating with a consensus price target of $330. Labcorp recently reported strong Q2 earnings, exceeding EPS estimates and showing a 5.8% year-over-year revenue increase, alongside declaring a quarterly dividend of $0.72 per share.
Out of sight, out of work? What’s driving remote job cuts
Some biopharma companies are reducing their remote workforce, forcing employees to choose between returning to the office, relocating, or resigning, as seen with EMD Serono and Exelixis. While many employers cite collaboration benefits for requiring on-site presence, other factors like program cuts or cost reductions also drive layoffs, affecting both remote and on-site staff. Experts suggest that job security remains a general industry risk, regardless of work location, though some candidates are wary of changing remote work policies.
Labcorp Holdings (LH) Could Be 2% Below Fair Value On NACHC Partnership
Labcorp Holdings (LH) has partnered with the National Association of Community Health Centers (NACHC), focusing on leadership development and practice improvement. Despite recent stock momentum, the company is considered 2% undervalued with a fair value of $337.75, driven by anticipated growth in new tests and efficiency gains from AI. However, its current P/E ratio is higher than the industry average, suggesting some valuation risk.
Fortrea Holdings COO Mark Morais sells $88,985 in company stock.
Fortrea Holdings COO Mark Morais sold 4,892 shares of company stock worth $88,985. This transaction was not a discretionary trade but was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). Following these transactions, Morais directly holds 77,786 shares and indirectly holds 4,625 shares through a spouse, in addition to 90,682 derivative securities.
Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Labcorp Holdings Inc. (LH) shares rose 2.56% to $330.44 on Wednesday, setting a new 52-week high, despite underperforming the broader market. The S&P 500 and Dow Jones Industrial Average also saw gains, rising 0.21% and 0.22% respectively. This performance indicates a strong trading session for the company and the market overall.
Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
Labcorp and the National Association of Community Health Centers (NACHC) have formed a strategic alliance to enhance leadership development, practice improvement, and community health initiatives across the U.S. Community Health Center network. A key component of this collaboration is the launch of the NACHC Leadership Exchange for Chief Medical Officers, designed to support current and emerging clinical leaders. The partnership aims to combine their expertise to improve healthcare delivery, strengthen quality performance, and leverage data to better patient outcomes.
Danica Pension Livsforsikringsaktieselskab Invests $2.26 Million in Quest Diagnostics Incorporated $DGX
Danica Pension Livsforsikringsaktieselskab has invested approximately $2.26 million in Quest Diagnostics Incorporated, acquiring 10,653 shares during the second quarter. Other institutional investors have also adjusted their holdings in DGX, with institutional ownership standing at 88.06%. Analysts have a "Moderate Buy" rating for Quest Diagnostics, with an average price target of $235.31, following strong quarterly earnings and revenue performance.
ELV|Elevance Health Inc|Price:399.980|Chg%:+9.740
This article provides a comprehensive stock analysis of Elevance Health Inc (ELV) from TradingKey, highlighting its stable fundamentals and significant growth potential. The company is considered fairly valued within the Healthcare Providers & Services industry and has received multiple "Buy" ratings from analysts. Despite average market performance recently, the stock is suitable for range-bound swing trading due to its sideways movement between support and resistance levels.
Labcorp (NYSE:LH) Director Sells $954,060.00 in Stock
Labcorp Director Kerrii Anderson sold 3,000 shares of the company's stock for $954,060.00, reducing her direct holdings by over 31%. This transaction occurred under a pre-arranged Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings, exceeding analyst expectations, and announced a quarterly dividend of $0.72 per share.
Labcorp director Kerrii B. Anderson sells $954,060 in shares
Labcorp director Kerrii B. Anderson sold 3,000 shares of the company's common stock for $954,060 on August 17, 2026, as part of a Rule 10b5-1 trading plan. Following the transaction, Anderson directly owns 6,563 shares, with additional shares held indirectly through separate trusts. The sale comes as Labcorp's stock trades near its 52-week high, and the company recently reported strong second-quarter earnings and announced executive leadership changes.
Labcorp (NYSE: LH) director sells $954K in preplanned trade
Labcorp director Kerrii B. Anderson sold 3,000 shares of common stock for approximately $954,060 on August 17, 2026. This transaction was executed under a Rule 10b5-1 trading plan. After the sale, Anderson directly holds 6,563 shares and indirectly holds 144 shares in each of two separate trusts.
Labcorp partners with NACHC to develop health center leaders By Investing.com
Labcorp and the National Association of Community Health Centers (NACHC) have announced a strategic alliance to enhance leadership development and practice improvement within the U.S. Community Health Center network. This collaboration includes the launch of the NACHC Leadership Exchange for Chief Medical Officers, aimed at supporting clinical leaders through executive development and peer mentorship. The partnership will also leverage de-identified laboratory data to help health centers improve patient outcomes and quality performance.
Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
Labcorp and the National Association of Community Health Centers (NACHC) have formed a strategic alliance to enhance leadership development, practice improvement, and community health initiatives across the nation's Community Health Center network. A key component of this collaboration is the launch of the NACHC Leadership Exchange for Chief Medical Officers, a program designed to strengthen the capabilities of clinical leaders serving health centers. This partnership aims to leverage Labcorp's expertise in diagnostics and analytics with NACHC's reach to improve healthcare delivery and patient outcomes for the millions of Americans served by CHCs.
Labcorp and NACHC Launch Strategic Alliance to Strengthen Health Center Leadership and Advance Community Health
Labcorp (NYSE: LH) and the National Association of Community Health Centers (NACHC) have formed a strategic alliance to enhance leadership development, practice improvement, and community health across the U.S. Community Health Center network, which serves 52.3 million patients. A key part of this collaboration is the launch of the NACHC Leadership Exchange for Chief Medical Officers, a program designed to build the capabilities of clinical leaders using Labcorp’s subject matter expertise. The alliance will also focus on educational initiatives and leveraging de-identified Labcorp data to improve quality performance and patient outcomes.
Labcorp (NYSE:LH) Sets New 12-Month High - Time to Buy?
Labcorp (NYSE:LH) recently reached a new 52-week high of $326.89, with analysts maintaining a "Moderate Buy" rating and an average price target of $330. The company reported strong quarterly earnings, exceeding estimates with EPS of $4.99 and revenue up 5.8% year-over-year. Despite some insider selling, institutional investors hold a significant majority of the stock, and Labcorp declared a quarterly dividend of $0.72 per share.
How Investors May Respond To Labcorp (LH) Expanding PTEN Dx Reach Amid Oncology Leadership Transition
Labcorp (LH) recently announced a leadership transition in its biopharma laboratory services and expanded its offering of Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay nationwide. This move aims to broaden access to companion diagnostic testing for prostate cancer, influencing Labcorp's oncology investment narrative. While these developments support Labcorp's positioning, the most significant near-term catalyst remains execution on higher-value test adoption, alongside the key risk of potential reimbursement pressure.
Labcorp Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains
Labcorp Holdings Inc. (LH) shares rose 1.64% on Monday, closing at $323.34, despite a generally negative trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw declines. This gain for Labcorp Holdings Inc. ended a two-day losing streak for the company's stock.
Labcorp stock hits all-time high at 325.75 USD
Labcorp (LH) stock has reached an all-time high of $325.75, showing a significant 27.5% year-to-date return and a 20.25% increase over the past year. This comes as the company reported strong second-quarter earnings, exceeding Wall Street expectations, and raised its full-year outlook. Despite 11 analysts revising earnings upwards, InvestingPro suggests the stock might be overvalued relative to its Fair Value.
Labcorp Holdings (LH) to Host Investor Day on September 10, 2026
Labcorp Holdings (LH) announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, CFO Julia Wang, and other executive team members will discuss the company's strategy, capital deployment, and long-term financial outlook. A live webcast will be available on the Labcorp Investor Relations website, with a replay and supporting materials accessible afterward.
Labcorp to hold Investor Day on Sept 10 to disc...
Labcorp Holdings Inc. announced it will host an Investor Day on September 10, 2026. CEO Adam Schechter and CFO Julia Wang will present the company's future strategy, capital priorities, and long-term financial outlook. The event will include a Q&A session and be webcast live, providing crucial insights for investors into Labcorp's plans.
Labcorp to Host Investor Day on September 10, 2026
Labcorp (NYSE: LH) announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, Executive Vice President and CFO Julia Wang, and other executive leaders will discuss the company's strategy, capital deployment, and long-term financial outlook, followed by a Q&A session. A live webcast and replay will be available on Labcorp's Investor Relations website.
Labcorp to host Investor Day Sept. 10 outlining strategy, capital priorities and outlook
Labcorp (LH) will host an Investor Day on September 10, 2026, to detail its strategy, capital allocation priorities, and long-term financial outlook. CEO Adam Schechter and CFO Julia Wang will present, followed by a Q&A session. A webcast replay and supporting materials will be available on the company's Investor Relations site.
Labcorp to Host Investor Day on September 10, 2026
Labcorp Holdings Inc. announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, Executive Vice President and CFO Julia Wang, and other executive leaders will discuss the company's strategy, capital deployment, and long-term financial outlook. A live webcast and replay will be available on the Labcorp Investor Relations website.
Illumina, Inc. (ILMN) Stock Analysis: A Closer Look At Growth Potential And Market Position
Illumina, Inc. (ILMN) is a key player in the Diagnostics & Research industry, specializing in genomic and genetic analysis solutions, with a market capitalization of $28.82 billion. Despite a recent stock dip, its strong return on equity of 32.34% and free cash flow of $797.6 million indicate robust financial health and efficient management. Analyst ratings are mixed but lean optimistic, with a consensus target price suggesting a modest upside, highlighting the company's growth potential in the evolving biotech sector while also noting inherent risks.
Diamond Hill Capital Management LLC Investment Advisor Makes New Investment in Labcorp Holdings Inc. $LH
Diamond Hill Capital Management LLC Investment Advisor has acquired a new stake in Labcorp Holdings Inc. (NYSE:LH), purchasing 600,792 shares valued at approximately $168.22 million, making it their 26th largest holding. Other institutional investors have also significantly increased their positions in Labcorp, while company insiders have sold shares. Analysts currently rate Labcorp as a "Moderate Buy" with a consensus target price of $330.00, and the company recently announced a quarterly dividend of $0.72 per share.
Labcorp Holdings Inc. stock outperforms competitors despite losses on the day
Shares of Labcorp Holdings Inc. (LH) experienced a 1.38% drop on Friday, closing at $318.13. Despite this loss and an overall poor trading day for the stock market, with the S&P 500 and Dow Jones also falling, Labcorp's stock still outperformed its competitors. This marks the second consecutive day of losses for the company.
Labcorp announces executive leadership changes effective in September
Labcorp (NYSE:LH) has announced executive leadership changes effective in September. Megan D. Bailey is resigning as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., will assume an expanded role as Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, responsible for both Early Development Research Laboratories and Central Laboratories businesses, effective September 1, 2026. The company also recently reported strong second-quarter results, surpassing Wall Street expectations, with adjusted earnings of $4.99 per share and revenue of $3.73 billion, and has raised its full-year outlook.
Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG
Several biotech stocks, including Park Dental Partners (PARK), Labcorp Holdings (LH), Hemab Therapeutics Holdings Inc. (COAG), Aveanna Healthcare Holdings (AVAH), and Candel Therapeutics Inc. (CADL), reached 52-week highs on August 13, 2026, driven by positive Q2 reports and increased financial guidance. These companies reported revenue growth and advancements in their services and drug pipelines, leading to significant stock price increases.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share that met estimates and revenues that surpassed them, leading to a slight increase in stock price. The company's net sales grew by 1% year-over-year, with strong organic growth in its Diagnostics and Spatial Biology segments. Bio-Techne is set to be acquired by Merck KGaA for $11.3 billion, and this transaction remains a key focus.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share of 52 cents, meeting analyst estimates, while revenues of $321.2 million surpassed expectations. Despite some segment-specific challenges and a contraction in adjusted gross margin, the company's shares rose following the announcement. The article also highlights Bio-Techne's pending acquisition by Merck KGaA for $73 per share, representing an enterprise value of approximately $11.3 billion.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share of 52 cents, meeting Zacks Consensus Estimates, while net sales of $321.2 million surpassed expectations. Despite some mixed segment performances and a contraction in adjusted gross margin, the company's shares rose slightly. The article also highlights Bio-Techne's agreement to be acquired by Merck KGaA for approximately $11.3 billion, which is progressing.
Quest Diagnostics Keeps Quarterly Dividend at $0.86 per Share, Payable Oct. 21, to Shareholders of Record Oct. 6
Quest Diagnostics (DGX) announced that it will maintain its quarterly dividend at $0.86 per share. This dividend will be payable on October 21, 2026, to shareholders of record as of October 6, 2026. The announcement was published on August 12, 2026, by MT Newswires.
Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 Million
Labcorp CEO Adam Schechter sold 4,669 shares of the company's stock for approximately $1.5 million on August 11, 2026. This transaction, executed under a Rule 10b5-1 plan, represents about 4% of his direct holdings and is considered routine portfolio management, not a change in outlook. Schechter retains 102,565 shares valued at $33 million, and the company continues to show strong financial performance with rising revenue and operating profits.
Labcorp president & CEO Adam Schechter sells $1.5m in company stock
Adam H. Schechter, President & CEO of Labcorp Holdings Inc., sold 4,669 shares of company stock for approximately $1.5 million. The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan. This transaction occurred as LH stock traded near its 52-week high, following a 29% year-to-date return, and after the company reported strong second-quarter results exceeding analyst expectations.
Insider Selling: Labcorp (NYSE:LH) CEO Sells 4,669 Shares of Stock
Labcorp CEO Adam Schechter sold 4,669 shares of company stock for approximately $1.50 million under a pre-arranged trading plan, reducing his total ownership by 4.35%. This sale occurred while Labcorp shares traded near their 52-week high, following strong quarterly earnings that surpassed analyst expectations. Analysts generally maintain a positive outlook on the stock with a consensus "Moderate Buy" rating and a target price of $330.
Labcorp president & CEO Adam Schechter sells $1.5m in company stock
Adam H. Schechter, President & CEO of LABCORP HOLDINGS INC. (NASDAQ:LH), sold 4,669 shares of company stock for $1,495,807 on August 11, 2026, executed via a pre-arranged Rule 10b5-1 trading plan. This sale occurred as LH stock approached its 52-week high after a strong 29% year-to-date return. Following the transaction, Schechter directly owns 102,565 shares, and the company recently reported strong second-quarter results exceeding analyst expectations.
Labcorp (LH) CEO Adam Schechter sells 4,669 shares at $320.37 under 10b5-1 plan
Labcorp (LH) CEO Adam H. Schechter sold 4,669 shares of common stock at a price of $320.37 per share on August 11, 2026. This transaction was conducted under a pre-established 10b5-1 trading plan. Following the sale, Schechter directly holds 102,565 shares of Labcorp common stock.
Onconetix (NASDAQ: ONCO) resale filing covers 100M shares tied to PIPE
Onconetix (NASDAQ: ONCO) has filed a Form S-1 registration statement for the resale of up to 100 million shares of common stock by selling stockholders, linked to a July 2026 PIPE financing. These shares are convertible from Series F preferred stock, with an initial conversion price of $0.9767 per share. The company will not receive any proceeds from these resales and faces significant financial challenges, including substantial net losses and doubt about its ability to continue as a going concern, despite efforts to commercialize its Proclarix prostate cancer diagnostic and pursue a Realbotix share exchange.
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
Freenome has received FDA Breakthrough Device Designation for its investigational blood-based SimpleScreen™ Lung cancer screening test. This AI-powered multiomic test is designed for high-risk adults aged 50-80 who are not currently undergoing guideline-recommended lung cancer screening. The designation aims to accelerate the development and review process for this potentially life-saving diagnostic tool, addressing the low screening rates for lung cancer, which is the leading cause of cancer death in the U.S.
Labcorp (LH) Stock Looks About Right On Raised Full Year Guidance
Labcorp (LH) stock appears to be fairly valued according to Discounted Cash Flow and P/E ratio analyses, following a 54.1% increase over the last three years and a recent raise in full-year guidance. The intrinsic value estimate is close to the current share price, suggesting the market has already factored in recent positive developments like oncology diagnostic progress. Future stock movement will likely depend on the company's ability to sustain cash flow quality and integrate new capabilities effectively.
Labcorp Holdings Inc. (NYSE:LH) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Labcorp Holdings Inc. (NYSE:LH) has received a consensus "Moderate Buy" rating from twelve brokerages, with an average 12-month price target of $330.00. The company recently surpassed quarterly earnings expectations with $4.99 EPS and $3.73 billion in revenue, and declared a quarterly dividend of $0.72 per share. Insider trading activity included sales by EVP Bryan T. Vaughn and EVP Amy B. Summy.
Labcorp Holdings Inc. Stock 12‑Month Price Target Raised to $345.79, Implies 7% Upside
Labcorp Holdings Inc.'s average 12-month stock price target has increased to $345.79 from $340.73, based on estimates from 14 analysts. This updated target suggests a potential upside of approximately 7% from the August 11 closing price. The consensus rating for LH remains a "Buy" among 20 covering analysts.
Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs
Alcon (ALC) reported stronger-than-expected Q2 2026 core earnings and revenues, leading to a 3.2% rise in its stock price. The company saw growth across its Surgical and Vision Care segments, driven by new product launches and price increases, despite some challenges in the implantables and cataract markets. Alcon also raised its full-year 2026 profitability outlook.
Fortrea (FTRE) Gains Traction in Turnaround
Investment management company Curreen Capital highlighted Fortrea Holdings Inc. (FTRE) in its Q2 2026 investor letter, noting its attractive upside-to-downside ratio. Fortrea, a contract research organization spun out of Labcorp in June 2023, is undergoing a business turnaround and saw a 10.09% year-to-date gain and a 159.78% gain over the past 52 weeks. Although 36 hedge funds held FTRE, Curreen Capital also suggested that certain AI stocks offer greater upside potential with less downside risk.
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Medical Ltd. reported its second-quarter 2026 financial results, highlighting significant clinical and corporate achievements. These include positive interim results from the REGAIN trial for recurrent glioblastoma, a strategic collaboration with Tolmar for prostate cancer, and the completion of patient enrollment for the ReSTART trial in cSCC. The company also announced strong financial standing with $104.8 million in cash and equivalents, supporting continued clinical advancement and commercial preparation.
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?
Labcorp (LH) is showing improved revenue growth, wider margins, and higher full-year guidance, particularly in specialty testing and biopharma services. However, its current valuation is considered rich, trading at a premium to its historical median and sub-industry multiple, which raises the bar for future execution. While the operating picture is improving, the high valuation suggests a balanced, rather than an automatic buy, approach to the stock, which currently holds a Zacks Rank #3 (Hold).
Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?
Labcorp Holdings Inc. (LH) is experiencing faster revenue growth, wider margins, and raised full-year guidance for 2026, driven by specialty testing and Biopharma Laboratory Services. However, its valuation is currently at a premium compared to its historical median and industry multiple, suggesting a more cautious investment approach. Despite improved operating performance and a strong Momentum Score, the high valuation and ongoing reimbursement and cost risks lead to a balanced outlook, reflected in its Zacks Rank #3 (Hold).
Guardant Health (GH) Is Up 6.1% After Raising 2026 Revenue Outlook And Filing Shelf Registration - Has The Bull Case Changed?
Guardant Health (GH) saw its stock rise 6.1% after increasing its 2026 revenue guidance to US$1.34–1.36 billion, driven by accelerated Shield screening adoption and new UnitedHealth coverage. While the raised outlook strengthens the bull case for sales growth, the company also filed a shelf registration, indicating a potential for future financing, which could lead to dilution if net losses persist. The article suggests that while sales are up, continued losses mean the core investment narrative remains largely unchanged, albeit with a stronger near-term catalyst in Shield adoption.
